Brief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
23/10/2026 23:14
BRIEF-Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results Oct 23 (Reuters) - Cumberland Pharmaceuticals Inc. CPIX.O:
CUMBERLAND PHARMACEUTICALS ANNOUNCES ASSIST-SSC TRIAL TOP-LINE RESULTS
CUMBERLAND PHARMACEUTICALS - IFETROBAN DEMONSTRATES SAFETY AND TOLERABILITY IN SYSTEMIC SCLEROSIS PATIENTS
CUMBERLAND PHARMACEUTICALS - IFETROBAN WELL TOLERATED; MOST GI ADVERSE EVENTS WERE MILD AND RESOLVED
CUMBERLAND PHARMACEUTICALS - NO SERIOUS ADVERSE EVENT RELATED TO IFETROBAN DURING 12-MONTH TREATMENT PERIOD
CUMBERLAND PHARMACEUTICALS - MODEST INCREASE IN MILD BLEEDING-RELATED ADVERSE EVENTS WITH IFETROBAN
Source text: ID:nPn3wlHVda
Further company coverage: CPIX.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Cumberland Pharmaceuticals
See all newsBrief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Brief: Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln
NASDAQ RESUMED AT 09:38 AM